Abstract
Introduction
Acquired immune deficiency syndrome (AIDS) is a serious infectious disease caused by human immunodeficiency virus (HIV) infection 1 . As a chronic infectious disease that can directly impair human immune system, AIDS has become one of the world's most serious diseases 2 . There are an estimated 39 million deaths caused by AIDS since its first recognition 3 . According to the UNAIDS data, nearly 37 million people worldwide lived with HIV at the end of 2014. About 1.2 million people died from HIV-related causes globally in 2014. Therefore, prevention and treatment of HIV/AIDS are of great significance for human health and social stability.
Many scientists around the world are dedicated to finding scientifically proven strategies for HIV prevention and treatment. The discovery of new anti-HIV drugs is the main way to treat and control With the widespread use of these drugs, it will result in cross-resistance and serious side effects. Therefore, the clinical application of these drugs is very limited 5, 8 . In addition, the discovery of anti-HIV target is greatly confined to a very small number of proteins encoded by the HIV genome.
HIV is an obligate intracellular pathogen and relies heavily on the host proteins for entry, replication and transmission. Therefore, we can achieve the goal of anti-HIV through targeting host proteins that are essential for HIV life cycle 8, 9 . According to the Integrity database, multiple In recent years, many studies discovered a large number of HIV-associated host proteins and 17, 19 . Furthermore, the proteins identified by these high-throughput screening methods may not be targeted by drug because of lacking druggability [20] [21] [22] . Currently, more than 4000 human proteins involved in the HIV-1 life cycle are documented in the HIV-1 Human Interaction Database 23 . Identifying appropriate anti-HIV targets from so many host proteins is crucial to anti-HIV drug development, but a challenging work.
Therefore, we aimed to identify novel human targets for anti-HIV therapy by anti-HIV activity prediction and enrichment (APE) method. In our previous study, we first used the APE method to infer anti-cancer targets and identified HKDC1 as a novel potential therapeutic target for cancer 24 . In this study, the APE method mainly contains two steps as shown in Figure 1 : anti-HIV activity prediction and enrichment analysis of anti-HIV activity. We firstly developed Anti-HIV-Predictor to predict the anti-HIV activity of a given compound by integrating three rapid and accurate computational methods.
Then the anti-HIV activities of all compounds with human targets in ChEMBLdb were predicted using Anti-HIV-Predictor. In the second step, we performed a hypergeometric test to determine the targets that significantly enriched with anti-HIV compounds. Using this strategy, we identified 73 potential human targets for anti-HIV therapy. These human targets directly or indirectly interact with HIV proteins through neuropeptide signaling, GPCR signaling, cell surface signaling pathway, and so on.
Nearly half of these targets overlap with the NCBI HIV dataset. However, the percentage of known therapeutic targets in these targets is significantly higher than that in the NCBI HIV dataset. In addition, 37 of these targets belong to G-protein coupled receptor family, which indicates that the GPCRs may be more important for HIV life cycle than ever known. After a series of feature analysis, we identified 13 novel human targets with high potential as anti-HIV targets. The inhibitors of the 13 novel targets have experimentally confirmed anti-HIV activity. The results of this study provide important ideas and guidance for the host-oriented anti-HIV drug development.
Results

Development and performance of Anti-HIV-Predictor
Anti-HIV-Predictor was developed to predict the anti-HIV activity of given compounds ( Figure   1 ). Anti-HIV-Predictor firstly integrated all the data of anti-HIV activity from ChEMBL and NCI database to construct a benchmark dataset. Then, using the benchmark dataset, three prediction models were generated by training, parameter selection and validation. The three models are relative frequency The classification performance of the models was assessed in terms of accuracy, precision, recall and F1 score (Figure 2) . As 10 runs of 5-fold cross-validation method were used, these scores were averaged. Over the 10 runs, their standard deviations were also reported. As shown in Figure 2 , the RFW_FP model obtains the statistical average of 93%, 87%, 90%, and 88% for accuracy, precision, recall, and F1 score, respectively. The accuracy, precision, recall, and F1 score of SVM model are 96%, 95%, 91%, and 93%, respectively. RF model performs best with accuracy of 96% and precision of 99%.
The overall performance of the RFW_FP, SVM and RF models was also quantified by receiver operating characteristic curve (ROC). For each model, the area under the curve (AUC) was calculated respectively. All three models achieve AUC value greater than 0.96, which reveals the excellent effectiveness of the models.
The characteristic of relationship between human targets and their ligands in ChEMBLdb
In order to infer potential anti-HIV human target, all human targets were downloaded from
ChEMBLdb. Their ligands whose activity is better than 10uM were also downloaded. Totally, we compounds are membrane receptor modulator. In addition, these compounds can also act on ion channels, transcription factors, transporters, epigenetic regulators and other proteins.
Prediction of anti-HIV activity for all compounds with human target in ChEMBLdb
To infer anti-HIV human targets by anti-HIV activity enrichment, we predicted the anti-HIV activity of the 251825 compounds that act on human proteins using Anti-HIV-Predictor. The results of the computational screen are shown in Figure 4 . The inactive compounds were shown as blue dots (RFW_TC P-value≥0.05, SVM probability and RF probability≤0.5). The green dots represent the compounds with anti-HIV activity supported by one or two models (RFW_TC P-value＜0.05 or SVM probability＞0.5 or RF probability＞0.5). The red dots represent the compounds with anti-HIV activity supported by all three models (RFW_TC P-value＜0.05 and SVM probability＞0.5 and RF probability
Inferring 73 potential anti-HIV human targets
The identification of anti-HIV human targets is of great value for the development of anti-HIV drugs. We have predicted tens of thousands of compounds with anti-HIV activity above. Based on the result, we can infer potential anti-HIV targets that enriched with anti-HIV compounds. A total of 73 human targets (P_adj＜0.05) were inferred using the APE method (Supplemental Table S1 ). These 
Comparison of the predicted targets in this study with NCBI HIV dataset
In order to compare our study with other studies, we downloaded all HIV-related host factors from HIV-1 interactions database in NCBI (Supplemental Table S3 ) 23 . Thus, these 73 targets represent potential anti-HIV human targets that should be validated further using other methods.
Identifying 13 novel human targets whose inhibitors have potent anti-HIV activity
To further evaluate the anti-HIV potential of the 73 targets, we checked whether the inhibitors of these targets have experimentally confirmed anti-HIV activity. We found 16 human targets whose inhibitors have anti-HIV activity through mapped the inhibitors into anti-HIV activity data from ChEMBLdb and NCI (Figure 7 and Table 1 ). Among them, CCR5, CXCR4 and ABCB1 are currently already used for anti-HIV therapy. The other 13 targets, highlighted with underline in Table 1, represent novel human targets identified in this study. Of the 13 novel targets, 4 targets have approved drugs for other diseases, 11 targets were used in clinical trials for other diseases (Table 1) . Furthermore, druggability of these novel targets. For most of these novel targets, the anti-HIV activities of their inhibitors are about 1 uM, which is at the same level of activity compared with known anti-HIV targets (Figure 7) . It is noteworthy that the inhibitors of REN and CALCA have better anti-HIV activity (0.136 uM, 0.102 uM, respectively) than CCR5 inhibitors (0.227 uM). Furthermore, the compound CHEMBL470508, the inhibitor of CTSD, show potent anti-HIV activity (0.008uM) than the approved anti-HIV drug maraviroc (0.016uM). Therefore, the 13 novel human targets identified in this study have high potential as the targets for HIV therapy.
Discussion
The failure of 30 years of HIV vaccine development 25, 26 , as well as the prevalence of drug-resistant HIV [27] [28] [29] , emphasizes the need for new, effective and affordable anti-HIV drugs. New target discovery will promote discovery of new anti-HIV drugs. Therefore, identifying host proteins as novel anti-HIV targets is crucial to the development of anti-HIV drugs, especially host-targeting drugs.
RNAi and CRISPR can be used to identify HIV-related host factors. However, there are some shortcomings for the two methods. RNAi-based screens have identified thousand candidate host factors, but there is little agreement among studies 19 . In contrast, CRISPR screen only discovered five host factors, two of which are known factors CCR5 and CD4 19 . Therefore, new methods for identification of human target are needed to improve this situation. In this study, benefited from massive activity data between target and compound in ChEMBLdb and NCI, we can identify potential human targets for anti-HIV therapy using the APE method. Firstly, we predicted 10488 compounds with anti-HIV activity from 251825 compounds in ChEMBLdb using Anti-HIV-Predictor. Then we inferred 73 human targets significantly enriched with predicted anti-HIV compounds by enrichment analysis. The success of maraviroc indicates host-targeting anti-HIV is an important strategy for the deployment of anti-HIV drugs. CCR5, as a protein on the surface of white blood cells, is involved in the immune system as it acts as G protein-coupled receptor for chemokines 30 . HIV initially uses CCR5 as co-receptor to enter and infect host cells 31 . G protein-coupled receptors signaling pathway can be hijacked by HIV revealed by previous studies 32 . The 73 human targets inferred by enrichment analysis are involved in G-protein coupled receptor signaling pathway (P-value=6.60E-11) and cell surface receptor signaling pathway (P-value=1.53E-9). Among them, 37 human targets belong to G-protein coupled receptor family (Supplemental Table S1 ). This result suggests the G protein-coupled receptor signaling pathway may be more important for HIV life cycle than ever known. Furthermore, these targets are significantly enriched in neuropeptide signaling pathway (P-value=2.3E-13). HIV infection will cause HIV-associated distal symmetric polyneuropathy and other HIV-related peripheral neuropathies. Our study indicates these targets may be involved in the neuropathy process induced by HIV infection.
We identified 13 novel human targets whose inhibitors have anti-HIV activity through mapped the inhibitors into anti-HIV activity data from ChEMBLdb and NCI (Figure 7 and Table 1 
Materials and methods
Construction of anti-HIV benchmark dataset and collection of information of targets and compounds
Anti-HIV activity data were downloaded from ChEMBLdb 33,34 and NCI 35 . In ChEMBLdb, the compound whose target is "human immunodeficiency virus type 1" and with the activity better than 10μmol/L was considered as active compounds. In NCI, the compound with more than 2 replication experiments and with EC 50 less than 10μmol/L was considered as active compounds. And the other compounds with EC 50 more than 100μmol/L were considered as inactive compounds. Finally, all compounds in the two databases were integrated by removed the conflict and replicated compounds. 
Development of Anti-HIV-Predictor
We incorporated three models (RFW_FP model, SVM model and RF model) as
Anti-HIV-Predictor to predict the anti-HIV activity of chemical compounds. The RFW_FP model was generated as follows. Relative Frequency-Weighted Fingerprint (RFW_FP) was used in our previous study and powerful to distinguish the active and inactive compounds for anti-cancer 24,36,37 . Firstly, RFW_FP was used to calculate the compound fingerprints as follows: where RFW_TC(m,n) is RFW_TC between two compounds m and n. S m and S n are the sum of RFW_FPs in compound m and n, respectively. S mn is the sum of the common RFW_FPs between two compounds. Finally, for each query chemical compounds, the maximum RFW_TC between the query and the active dataset (9584 compounds) was calculated. Then the P-value was calculated based on the maximum RFW_TC. As the maximum RFW_TC is less than 1.0 and the maximum RFW_TCs of the inactive compounds have a normal distribution (Figure S3) , we can calculate the P-value as follows:
where p(χ) is the P-value at the maximum RFW_TC of x; F(χ;μ,σ) is the cumulative function of normal distribution. Using the maximum likelihood method ("fitdist" function in R "fitdistrplus" package The RF model was generated as follows. The algorithm of random forest is based on the ensemble of a large number of decision trees, where each tree gives a classification and the forest chooses the final classification having the most votes over all the trees in the forest 45 . Random forest, implemented in Scikit-learn 43 , was used as a classifier with the following settings: (1) Number of trees was set to 900
(n_estimators =900). This parameter was selected by calculating AUC ( Figure S5) . (2) The minimum number of samples to split an internal node was set to 2 (min_samples_split = 2, default setting). (3) The minimum number of samples in newly created leaves was set to 1 (min_samples_leaf = 1, default setting). (4) The number of features to consider when looking for the best split was set to the square root of the number of descriptors (max_features = auto, default setting). (5) The maximum depth of the tree was expanded until all leaves are pure or until leaves contain less than min_samples_split samples (max_depth = none, default setting). (6) Bootstrap samples were used (bootstrap = true, default setting).
For further documentation on the random forest implementation in Scikit-learn, the interested reader is referred to the website (http://scikit-learn.org).
Performance evaluation of Anti-HIV-Predictor
To test the performance of Anti-HIV-Predictor, 10 runs of 5-fold cross-validation (CV) method (Part 2 of Supplemental material) were used to the three models (RFW_FP model, SVM model and RF model). For each model, the ROC was plotted and the area under the curve (AUC) was calculated.
The results of the CV tests were used to calculate the four quality indices: accuracy, precision, recall and F1 score. We used the default statistical definition for these quality indices: 
Prediction of all compounds in ChEMBLdb using Anti-HIV-Predictor
All compounds with human target were downloaded from ChEMBLdb. A total of 251825 compounds and 1924 targets were obtained. They formed 384768 target-compound pairs. The anti-HIV activities of all compounds were predicted using Anti-HIV-Predictor. All compounds were screened rapidly by the three models. The cutoffs for RFW_TC model, SVM model and RF model are 0.05 (P-value), 0.5 (probability) and 0.5 (probability), respectively. The compound is predicted as anti-HIV compound if its anti-HIV activity supported by all three models (RFW_TC P-value＜0.05 and SVM probability＞0.5 and RF probability＞0.5). Totally, 10488 compounds were predicted as anti-HIV compounds (Supplemental Table S2 ).
Inferring the anti-HIV targets by enrichment analysis
After anti-HIV activity prediction of the 251825 compounds, we measured whether a target has the potential ability of anti-HIV using the APE method. The APE method is based on the results of anti-HIV activity prediction and uses a hypergeometric test to perform enrichment analysis. The P-value of each target can be calculated using the following equation:
Here, N and n are the total number of compounds and the total number of anti-HIV compounds in ChEMBLdb, respectively; m and k represent the number of compounds and the number of anti-HIV compounds for a target, respectively. Both n and k are calculated above using Anti-HIV-Predictor.
Because multiple tests (1924 targets) were performed, the Bonferroni correction method was used to adjust the P-value:
Here, P_adj is the adjusted P-value, P is the P-value of the hypergeometric test (without Bonferroni correction) and Ng is the number of human targets in the ChEMBLdb. Only targets with P_adj＜0.05 were considered as potential anti-HIV targets.
Multiple features analysis of the potential anti-HIV targets
We studied these potential targets in details by analyzing multiple features including biology function, pathway, interaction, and druggability. The biology function and pathway of these targets were analyzed by GO and KEGG annotation in DAVID web server 46 . The interactions of these targets were obtained by GeneMANIA analysis 47, 48 . The interactions of these targets with HIV proteins were obtained from NCBI HIV-1 human interaction database (Supplemental Table S3 ) 23 . The network of interaction was visualized using Cytoscape v3.2 49 . The druggability of these targets was analyzed by comparing with the lists of approved targets and clinical targets (Supplemental Table S4 
